Tomonori Kobayakawa

Fukuroi, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Author response to the letter to the editor regarding "Hip Response to Romosozumab in Glucocorticoid Users: Beyond Systemic Bone Turnover Markers".

Author response to the letter to the editor regarding "Hip Response to Romosozumab in Glucocorticoid Users: Beyond Systemic Bone Turnover Markers".

Journal: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Published: June 05, 2026

Is Early Injection-Site Reaction Associated With the Efficacy of Romosozumab?

Is Early Injection-Site Reaction Associated With the Efficacy of Romosozumab?

Journal: Cureus

Published: May 15, 2026

Impact of oral glucocorticoids on the effectiveness of romosozumab: the multicenter OASIS cohort study.

Impact of oral glucocorticoids on the effectiveness of romosozumab: the multicenter OASIS cohort study.

Journal: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Published: February 19, 2026

Baseline serum PINP is associated with early lumbar spine bone mineral density gains during twice-weekly teriparatide treatment: the OASIS cohort study.

Baseline serum PINP is associated with early lumbar spine bone mineral density gains during twice-weekly teriparatide treatment: the OASIS cohort study.

Journal: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Published: December 11, 2025

Author response to letter to the editor, "PINP-guided osteoporosis treatment selection: methodological considerations for cut-off, endpoint, fracture confounding and teriparatide heterogeneity".

Author response to letter to the editor, "PINP-guided osteoporosis treatment selection: methodological considerations for cut-off, endpoint, fracture confounding and teriparatide heterogeneity".

Journal: Bone

Published: November 09, 2025

Author response to letter to the editor, "Comment on "Impact of baseline PINP on the BMD increase with romosozumab, teriparatide, and denosumab in treatment-naïve primary osteoporosis: A retrospective cohort study"".

Author response to letter to the editor, "Comment on "Impact of baseline PINP on the BMD increase with romosozumab, teriparatide, and denosumab in treatment-naïve primary osteoporosis: A retrospective cohort study"".

Journal: Bone

Published: October 27, 2025

Renal function predicts 12-month response to romosozumab readministration after denosumab in women with osteoporosis.

Renal function predicts 12-month response to romosozumab readministration after denosumab in women with osteoporosis.

Journal: Archives of osteoporosis

Published: September 08, 2025

Age-related response to 12-month romosozumab in treatment-naïve Japanese women aged 55-100 years with primary osteoporosis.

Age-related response to 12-month romosozumab in treatment-naïve Japanese women aged 55-100 years with primary osteoporosis.

Journal: Bone

Published: August 29, 2025

Effectiveness of denosumab, teriparatide and romosozumab for glucocorticoid-induced osteoporosis: a propensity score-matched cohort study.

Effectiveness of denosumab, teriparatide and romosozumab for glucocorticoid-induced osteoporosis: a propensity score-matched cohort study.

Journal: Rheumatology (Oxford, England)

Published: August 22, 2025

Impact of baseline PINP on the BMD increase with romosozumab, teriparatide, and denosumab in treatment-naïve primary osteoporosis: A retrospective cohort study.

Impact of baseline PINP on the BMD increase with romosozumab, teriparatide, and denosumab in treatment-naïve primary osteoporosis: A retrospective cohort study.

Journal: Bone

Published: June 20, 2025

Effects of concomitant methotrexate and predictors of remission in Janus kinase inhibitor therapy for rheumatoid arthritis.

Effects of concomitant methotrexate and predictors of remission in Janus kinase inhibitor therapy for rheumatoid arthritis.

Journal: Joint bone spine

Published: April 03, 2025

Comparable Clinical Effectiveness of Baricitinib and Filgotinib in Patients With Rheumatoid Arthritis.

Comparable Clinical Effectiveness of Baricitinib and Filgotinib in Patients With Rheumatoid Arthritis.

Journal: International journal of rheumatic diseases

Published: March 22, 2025

Showing 1-12 of 40

Last Updated: 09/26/2026